IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Union Savings Bank

Union Savings Bank lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,000 shares of the company’s stock after selling 436 shares during the quarter. IDEXX Laboratories comprises about 1.3% of Union Savings Bank’s portfolio, making the stock its 12th biggest holding. Union Savings Bank’s holdings in IDEXX Laboratories were worth $2,220,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Valley National Advisers Inc. lifted its position in IDEXX Laboratories by 84.6% in the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after buying an additional 22 shares during the last quarter. Private Wealth Management Group LLC purchased a new stake in IDEXX Laboratories during the fourth quarter worth about $34,000. Venturi Wealth Management LLC increased its stake in IDEXX Laboratories by 226.3% during the fourth quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after purchasing an additional 43 shares during the period. Geo Capital Gestora de Recursos Ltd purchased a new stake in IDEXX Laboratories during the third quarter worth about $28,000. Finally, Covestor Ltd increased its stake in IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after purchasing an additional 28 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on IDXX. Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a research note on Tuesday, January 30th. JPMorgan Chase & Co. upped their target price on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Barclays cut their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Finally, StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, May 14th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $580.38.

Insider Activity

In other news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the sale, the director now directly owns 161 shares of the company’s stock, valued at $87,068.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Down 0.1 %

IDEXX Laboratories stock traded down $0.50 during mid-day trading on Wednesday, hitting $517.94. The company had a trading volume of 494,511 shares, compared to its average volume of 453,342. The stock has a market cap of $42.78 billion, a price-to-earnings ratio of 50.19, a PEG ratio of 4.17 and a beta of 1.27. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. The business has a fifty day moving average of $511.06 and a 200 day moving average of $522.11.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.68 by $0.13. The company had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.